Back to search

University of Southampton

Targeting myofibroblastic cancer-associated fibroblasts to overcome T cell exclusion from tumours

Abstract

dc:description.abstract

Immune checkpoint blockade therapy (ICBT) has revolutionised cancer treatment, yet its efficacy remains limited to subset of patients. A significant barrier to successful treatment is the restricted infiltration of CD8+ T cells into the tumour microenvironment (TME). Cancer-associated fibroblasts (CAFs), a key component of the TME, are highly heterogeneous and perform diverse functions, including influencing immune exclusion. Myofibroblastic CAFs (myCAFs) have been implicated in immune-excluded tumours and poor ICBT responses, highlighting the need for CAF-targeting strategies to enhance immunotherapy efficacy. <br/><br/>This thesis investigates the role of ataxia-telangiectasia mutated (ATM) in regulating the myCAF phenotype. We demonstrate that pharmacological inhibition of ATM in TGF-β1-differentiated fibroblasts leads to the downregulation of extracellular matrix (ECM)-associated genes and myCAF markers, while upregulating iCAF markers and altering cytokine composition. These changes correlate with enhanced CD8+ T cell migration in vitro. Next, we explore the role of specific CAF-derived ECM proteins, CTHRC1, POSTN, and COL11A1 on myCAF phenotype and function. Using CRISPR-Cas9 knockout models, we assess whether targeting these genes influences CD8+ T cell migration into tumours and enhances tumour suppressive properties in mouse models. We then investigate the activation of the cGAS-STING pathway in fibroblasts following ATM inhibition. We demonstrate that TGF-β1 suppresses the cGAS-STING pathway, whereas ATM deficiency induces a type I interferon response. Using mouse models, we show that targeting fibroblast ATM promotes intratumoural CD8+ T cell infiltration and that STING expression in myCAFs is essential for suppressing tumour growth in myCAF-rich environments. Finally, we evaluate the effects of different doses of the ATM inhibitor AZD0156 on key cellular processes, including target activity inhibition, cell proliferation, cell cycle progression, DNA synthesis, and regulation of myofibroblastic markers. Our findings demonstrate that AZD0156 is effective at low doses, which may have clinical applications in minimising potential toxicities. <br/><br/>Our work identifies a novel pathway regulating myCAF differentiation and provides a rationale for using ATM inhibitors to overcome CAF-mediated immunotherapy resistance. By investigating ECM-targeting and ATM inhibition, we uncover new therapeutic avenues to enhance immune infiltration and improve ICBT efficacy in solid tumours. <br/>

Degree

thesis:*
Name dc:type.qualificationname
Ph.D.
Level dc:type.qualificationlevel
doctoral
Grantor dc:publisher.institution
University of Southampton
Year dc:date.issued
2025

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Piotrowska, Klaudia
Advisors dc:contributor.advisor
  • Thomas, Gareth
  • Fenton, Tim
ORCID person:identifier.orcid

Rights

Language dc:language
English, eng

Chain of custody

source
Harvested from
University of Southampton
Base URL
eprints.soton.ac.uk/cgi/oai2
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Piotrowska, Klaudia. Targeting myofibroblastic cancer-associated fibroblasts to overcome T cell exclusion from tumours. doctoral thesis, University of Southampton, 2025.